New pharmacological treatment options for chronic constipation

Bibliography

• Bharucha AE, Pemberton JH, Locke GR III. American Gastroenterological Association technical review on constipation. Gastroenterology 2013;144:218-38
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Tack J, Müller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation-a European perspective. Neurogastroenterol Motil 2011;23:697-710
   PubMed Web of Science ®Google Scholar
• Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:772-81
   PubMed Web of Science ®Google Scholar
• Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013;145:749-57
   PubMed Web of Science ®Google Scholar
• Ford AC, Vandvik PO. Irritable bowel syndrome. Clin Evid (Online) 2012
   PubMedGoogle Scholar
• Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 2011;60:209-18
   PubMed Web of Science ®Google Scholar
• Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized Clinical Trial: macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome. Am J Gastroenterol 2013;108:1508-15
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112
   PubMed Web of Science ®Google Scholar
• Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423:71-83
   PubMed Web of Science ®Google Scholar
• Van De Velde VJ, Ausma J, Vandeplassche G. I.V. kinetics and absolute oral bioavailability of prucalopride [abstract]. Gastroenterology 2010;138(5 Suppl 1):S-230
   Google Scholar
• Van De Velde VJ, Ausma J, Vandeplassche G. Food does not affect the oral bioavailability of prucalopride [abstract]. Gastroenterology 2009;136:A536
   Web of Science ®Google Scholar
• Van de Velde VJ, Ausma J, Vandeplassche G. Proceedings of 16th United European Gastroenterology Week; 18th - 22nd December 2008; Vienna. Pharmacokinetics of prucalopride (Resolor) in man [abstract no. P0891]. Gut 2008;57(Suppl II):A282
   Google Scholar
• Van De Velde VJ, Ausma J, Vandeplassche G. Comparative pharmacokinetics of prucalopride in healthy young and elderly subjects [abstract]. Gastroenterology 2010;138(5 Suppl 1):S-230
   Google Scholar
• Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr 2013;57:197-203
   PubMed Web of Science ®Google Scholar
• Cellek S, John AK, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006;18:853-61
   PubMed Web of Science ®Google Scholar
• Prins NH, van Der Grijn A, Lefebvre RA, et al. 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132:1941-7
   PubMed Web of Science ®Google Scholar
• De Winter BY, Boeckxstaens GE, De Man JG, et al. Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 1999;45:713-18
   PubMed Web of Science ®Google Scholar
• Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13:465-72
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42:511-16
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-6
   PubMed Web of Science ®Google Scholar
• Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13:1493-7
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-60
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-67
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-56
   PubMed Web of Science ®Google Scholar
• Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34:870-7
   PubMed Web of Science ®Google Scholar
• Marquis P, De La Loge C, Dubois D, et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005;40:540-51
   PubMed Web of Science ®Google Scholar
• Tack J, Quigley E, Camilleri M, et al. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. UEGJ 2013;1:48-59
   PubMed Web of Science ®Google Scholar
• Tack J, Stanghellini V, Dubois D, et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2013. [Epub ahead of print]
   Google Scholar
• Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24:999-e541
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010;22:991-8. e255
   PubMed Web of Science ®Google Scholar
• Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55:2912-21
   PubMed Web of Science ®Google Scholar
• Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37:431-6
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002;97:194-7
   PubMedGoogle Scholar
• Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, 1 study. Aliment Pharmacol Ther 2012;35:48-55
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, Baró I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. J Pharmacol Exp Ther 2001;299:1007-12
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009;156:362-76
   PubMed Web of Science ®Google Scholar
• Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol 2012;73:203-9
   PubMed Web of Science ®Google Scholar
• Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32:1113-23
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256-e117
   PubMed Web of Science ®Google Scholar
• Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 2011;130:71-82
   PubMed Web of Science ®Google Scholar
• Busby RW, Kessler MM, Bartolini WP, et al. Pharmacological properties, metabolism and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013;344:196-206
   PubMed Web of Science ®Google Scholar
• Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;22:312-e84
   PubMed Web of Science ®Google Scholar
• Silos-Santiago I, Hannig G, Eutamene H, et al. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation. Pain 2013;154:1820-30
   PubMed Web of Science ®Google Scholar
• Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-c and extracellular cyclic GMP. Gastroenterology 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Feng B, Kiyatkin ME, La JH, et al. Activation of guanylate cyclase-C attenuates stretch responses and sensitization of mouse colorectal afferents. J Neurosci 2013;33:9831-9
   PubMed Web of Science ®Google Scholar
• Kurtz CB, Fitch D, Busby RW. Effects of a multidose administration of MD-1100 on safety, tolerability, exposure and pharmacodynamics in healthy subjects. Gastroenterology 2006;130:A26
   PubMed Web of Science ®Google Scholar
• Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 2009;104:125-32
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
   PubMed Web of Science ®Google Scholar
• Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36
   PubMed Web of Science ®Google Scholar
• Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
   PubMed Web of Science ®Google Scholar
• Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010;139:1877-86
   PubMed Web of Science ®Google Scholar
• Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-24
   PubMed Web of Science ®Google Scholar
• Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702-12
   PubMed Web of Science ®Google Scholar
• Guidance for Industry, Irritable Bowel Syndrome, Clinical Evaluation of Drugs for Treatment. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdf
   Google Scholar
• Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013;37:49-61
   PubMed Web of Science ®Google Scholar
• EMA guideline on irritable bowel syndrome (IBS). CPMP/EWP/785/97 (March 2003)
   Google Scholar
• Rao SS, Quigley EM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2013. [Epub ahead of print]
   Google Scholar
• Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013;11:1084-92
   PubMed Web of Science ®Google Scholar
• Berntgen M, Enzmann H, Schabel E, et al. Linaclotide for treatment of irritable bowel syndrome-The view of European regulators. Dig Liver Dis 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Shailubhai K, Comiskey S, Foss JA, et al. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci 2013;58:2580-6
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov NCT01429987, NCT01919697, NCT01722318
   Google Scholar
• Tack J, Corsetti M. Elobixibat. Ileal sodium-dependent bile acid transporter (IBAT) inhibitor agent for constipation. Drugs Future 2012. [Epub ahead of print]
   PubMedGoogle Scholar
• Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:1270-5
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012;10:1009-15
   PubMed Web of Science ®Google Scholar
• Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation–a double-blind study. Aliment Pharmacol Ther 2011;34:41-50
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transport inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154-64
   PubMed Web of Science ®Google Scholar
• Cremonini F, Mullan BP, Camilleri M, et al. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002;16:1781-90
   PubMed Web of Science ®Google Scholar
• Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106:1803-12
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov NCT01895543, NCT01827592, NCT01833065
   Google Scholar
• Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005;100:936-71
   PubMed Web of Science ®Google Scholar
• Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev 2010;7:CD007570
   PubMedGoogle Scholar
• Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007;102:1436-41
   PubMed Web of Science ®Google Scholar
• Cinca R, Chera D, Gruss HJ, Halphen M. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation – a comparison in a controlled environment. Aliment Pharmacol Ther 2013;37:876-86
   PubMed Web of Science ®Google Scholar
• Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol 2007;102:1964-71
   PubMed Web of Science ®Google Scholar
• Corazziari E, Badiali D, Habib FI, et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in treatment of chronic nonorganic constipation. Dig Dis Sci 1996;41:1636-42
   PubMed Web of Science ®Google Scholar
• Christie AH, Culbert P, Guest JF. Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics 2002;20:49-60
   PubMed Web of Science ®Google Scholar